Dr Lal PathLabs Q1 PAT up 28%, declares Rs 5 interim dividend
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.0 pts more than Nifty Smallcap 250 and 4.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr Lal PathLabs reported Q1 FY27 results with consolidated revenue up 19 percent YoY to Rs 7,977 million and profit up 27 percent to Rs 1,705 million. Standalone PAT grew 28 percent to Rs 1,659 million. Board declared Rs 5 interim dividend per share (50 percent on face value), record date July 30, 2026. Company completed 100 percent acquisition of Shahbazkers Diagnostic for Rs 200 million and announced 80 percent stake buy in Ghana-based Sunshine Healthcare and 30 percent in Neuome Technologies.
Strong Q1 earnings and dividend payout signal financial health. Africa and tech acquisitions widen footprint. Positive for shareholders.